{"name":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","slug":"cspc-baike-shandong-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"cspcbaikeshandongbiopharmaceutical.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"TG103","genericName":"TG103","slug":"tg103","indication":"Other","status":"phase_3"},{"name":"Placebo of CM326","genericName":"Placebo of CM326","slug":"placebo-of-cm326","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Dulaglutide,QW","genericName":"Dulaglutide,QW","slug":"dulaglutide-qw","indication":"Type 2 diabetes","status":"phase_2"},{"name":"HD1916","genericName":"HD1916","slug":"hd1916","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Omalizumab for injection","genericName":"Omalizumab for injection","slug":"omalizumab-for-injection","indication":"Moderate to severe persistent asthma","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"SYN008","genericName":"SYN008","slug":"syn008","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"TG103","genericName":"TG103","slug":"tg103","phase":"phase_3","mechanism":"TG103 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.","indications":[],"catalyst":""},{"name":"Dulaglutide,QW","genericName":"Dulaglutide,QW","slug":"dulaglutide-qw","phase":"phase_2","mechanism":"GLP-1 receptor agonist","indications":["Type 2 diabetes"],"catalyst":""},{"name":"HD1916","genericName":"HD1916","slug":"hd1916","phase":"phase_3","mechanism":"HD1916 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Omalizumab for injection","genericName":"Omalizumab for injection","slug":"omalizumab-for-injection","phase":"phase_3","mechanism":"Omalizumab is a monoclonal antibody that targets the IgE molecule, preventing it from binding to its receptor on mast cells and basophils.","indications":["Moderate to severe persistent asthma","Chronic idiopathic urticaria"],"catalyst":""},{"name":"Placebo of CM326","genericName":"Placebo of CM326","slug":"placebo-of-cm326","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"SYN008","genericName":"SYN008","slug":"syn008","phase":"phase_3","mechanism":"SYN008 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNRzdOSk9QYjdPQlBFbFItbmpMU09FcktoeGlvdW5oay1taG1PNnhpRnpwamxlRV9hU0NsRXEtR1dNZ05mY0VTRHUwR0U3cVc5RGZUQ2VPNmlNN2JzaUVWMVNjeU51Y2htTE9KaHJrSUdmM19acjZvcE5pTXVDazRNRHhOWW03SHYyZTMtMW5jSlVYa3drVUhWMnZteGRWWVRYYUFIeTN4NXczYWV4TkIyTGpWN3V6NGFhdkp1c3p4YTZGZjJCOEV6eUc3OU16UTJtaHRzOWd6VzZBSmE4bExfSmd0R3g0QWlZTFRrS3kzN1Z3aGwtbi1xT0dKWUNGNXdKTE80?oc=5","date":"2025-09-05","type":"pipeline","source":"PR Newswire UK","summary":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPNENwZFNOUy00TGpWSmJHbWV1V2UwQU5QWjAyd2owSUdlcWV2aThqZDktLXdJLVJubmVIMFQtal8zRlgxTEY2T1U0eWFYU2d3enMwMXdYaHN4NjZKSGxOTTRTdzRXX2tFVzZOSlFLYW5ZOTE2Y1FIcXB5dFhFd2ZfdS1jdDRXVUpvTG1mUjZrYk9tcFIzbGl3YWVWZV90T3EwZ1pSeEVRdWhVT0dOb1JMZnMzMGJ1VVhWeUVxdG1hRGVia04zNnZGVTRKQUUxU3FRN0dFRGtHejlKRnJmMEx4R2x5Xzc1QVAyNS16R1A3WkFxR1VvZHdyUTREWnJYa2h2cUJlUVVmN29XMFVxZWk0MEtUdTlSWGs3Y0VNdnNCMXNCOUlieDZyTHgtX2FpYnJBN1E?oc=5","date":"2025-07-14","type":"pipeline","source":"PR Newswire","summary":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight - PR Newswire","headline":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNZXZKd0Z2NVFoNlVjMGplZzBaam5BelR2VTI3YXh1Y2p5bUlOYUV0bnFGTFNlX3NpbDJFa2RvLVZLNlowWWMxMG5Cd3ZhVlgyZ25OUGk4cFdiXzJDUXdRR2JQNTJnVFB4WTdHbTlSRlFwczJHQ1hOWVdoYVJjUnN6ZzY1TU80ZmU3dk5BTjBXYTg5VXk4cHh3ZXpWN0VtYmZKNXNHMTFuTjdOV3JoQVFDNWdlMlZValVRZ1lEZVJscWxOcVVNUHhtbF91MUswMmdQMnA0SQ?oc=5","date":"2025-04-10","type":"pipeline","source":"PR Newswire","summary":"XENICAL Strengthens Market Position as Obesity Rates Surge Worldwide | DelveInsight - PR Newswire","headline":"XENICAL Strengthens Market Position as Obesity Rates Surge Worldwide | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNZjVyUVRCNTZDcUxOYlNzd1dRSWZrUE1Qdlh1cEVNY2VHT0c0YU93U1ZuVnpCbzBlMDBkcUxGeHlFbktQbmhaQmpLOGF4bm92cDUxbHpTLUtlbzJ2amVnVy1ieXlsWElUcDRWQ0pYc1Q1N2c1R3hzS1lGcTM4R3dIV1hyTS1Ma0JCRlc5MGduX3V0REYxOVN3QmUwSVFReUVVX3VaUUV3SUJsTGlZTzYtZmFua0NIUnprUmp1V1N0amtUOHNzMTZPbEdQQkhpZ3NnYVI3cENlY25CcXktR3dmaFR0aGIzUExRaE95WmYwRzk1b0kzenNaLWVRMVk5Zw?oc=5","date":"2025-02-27","type":"pipeline","source":"GlobeNewswire","summary":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight - GlobeNewswire","headline":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNaXpTSm1oUmI0UHJMaFVteVNtOXNJd0Zadm03Q0VKbHFmcG50R2hzcW9JV2VUOXNGdFFrTXJBWWQ0Q0VPUzRteDBMM184djRsUnE2cVQwM3BfSmhtLUo4bEVKcERlX3U2ekhLQU1Za2RTN3hPdzlXcnNpUUR3QjlSOGxtVFl2LWhqaFJDN2U0N09vbDVNYjlKODBXUDNHQi1idm80VzVB?oc=5","date":"2024-05-24","type":"patent","source":"BioWorld News","summary":"Celltrion’s Omlyclo gets nod as Europe’s first Xolair biosimilar - BioWorld News","headline":"Celltrion’s Omlyclo gets nod as Europe’s first Xolair biosimilar","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}